Skip to main content
. 2017 Sep 19;12:6973–6984. doi: 10.2147/IJN.S139011

Figure 6.

Figure 6

Overlaid in vitro MRI scans showing the difference in binding specificity and negative enhancement effect on T2-weighted values between PC-3 and normal prostate cells RC77N/E. Both cells were treated with (A) 5 and (B) 10 pmol of NT-IONPs, LHRH-IONPs, AE105-IONPs, and LHRH-AE105-IONPs. (C) Comparison of the reduction in T2 values between PC-3 cells and RC77N/E cells treated with IONPs. (D) T2 maps correlated with a reduction in T2 values.

Abbreviations: MRI, magnetic resonance imaging; NT-IONPs, non-targeted IONPs; LHRH-IONPs, luteinizing hormone-releasing hormone receptor peptide-targeted IONPs; AE105-IONPs, urokinase-type plasminogen activator receptor peptide-targeted IONPs; LHRH-AE105-IONPs, LHRH peptide- and AE105 peptide-targeted IONPs; IONPs, iron oxide nanoparticles; TE, echo time.